
Sign up to save your podcasts
Or
New GLP-1 weight-loss drugs have already hit $50 billion in annual sales – and look to have plenty of room to grow.
Portfolio Manager Dan Lyons joins this episode of Global Perspectives to provide an update on popular GLP-1 weight-loss therapies and discuss whether sales of the drugs can continue to grow and the impact on the overall healthcare sector.
4.7
1414 ratings
New GLP-1 weight-loss drugs have already hit $50 billion in annual sales – and look to have plenty of room to grow.
Portfolio Manager Dan Lyons joins this episode of Global Perspectives to provide an update on popular GLP-1 weight-loss therapies and discuss whether sales of the drugs can continue to grow and the impact on the overall healthcare sector.
497 Listeners
189 Listeners
2,174 Listeners
992 Listeners
1,789 Listeners
279 Listeners
804 Listeners
284 Listeners
181 Listeners
885 Listeners
1,267 Listeners
1,546 Listeners
416 Listeners
41 Listeners
3 Listeners
26 Listeners